Since the FDA's approval of rasburicase use for the treatment of tumor lysis syndrome, multiple cases of rasburicase-induced methemoglobinemia and hemolytic anemia have been reported among patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- TRADE NAMES: Elitek (Sanofi-Aventis); Fasturtec; Uricozyme
- INDICATIONS: Hyperuricemia (associated with tumor lysis syndrome)
- CLASS: Antimetabolite, Urate oxidase
- HALF-LIFE: 18 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
ANAPHYLAXIS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
